Back to results
US 2021/0275563 A1Published application
Highly active compounds against covid-19
AssigneeAtea Pharmaceuticals, Inc.
InventorsJean-Pierre Sommadossi, Adel Moussa
Life of this patent
Estimating the term…
Abstract
The present invention is the use of a small group of purine nucleotide phosphoramidate disclosed herein or a pharmaceutically acceptable salt thereof in an effective amount for the treatment or prevention of the novel 2019 coronavirus disease (COVID-19) in a host, for example a human, in need thereof.
Claims17
A method for the treatment of the 2019 coronavirus disease (COVID-19) caused by the SARS-CoV-2 virus in a human in need thereof comprising providing an effective amount of a compound of the formula:
- or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier wherein:
- R5 is selected from
- and R6;
- and
- R6 is a stabilized phosphate prodrug that metabolizes in vivo to a monophosphate, diphosphate, or triphosphate.
2 more elements
Dependencies are inferred from the claim text.